An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications
Tóm tắt
Từ khóa
Tài liệu tham khảo
Positive Results from Phase 2b Study of Ophthotech's Novel Anti-PDGF Combination Agent Fovista to be Presented at AAO Retina Subspecialty Day. Ophthotech website. http://www.ophthotech.com/news/positive-results-from-phase-2b-study-of-ophthotechs-novel-anti-pdgf-combination-agent-fovista-to-be-presented-at-aao-retina-subspecialty-day. Published October 24 2012. Accessed December 21 2016.
Tyrogenex Presents Final Results from Phase 1 Study of X-82 for Wet AMD at the 2015 Annual American Academy of Ophthalmology Meeting. PR Newswire website. http://www.prnewswire.com/news-releases/tyrogenex-presents-final-results-from-phase-1-study-of-x-82-for-wet-amd-at-the-2015-annual-american-academy-of-ophthalmology-meeting-300178524.html. Published November 13 2015. Accessed December 21 2016.
Focused Pipeline of CSC Treatments for Multiple Blinding Eye Diseases. Clearside Biomedical website. http://clearsidebio.com/product-portfolio. Accessed December 21 2016.
OHR-102 (Squalamine). OHR Pharmaceutical website. http://www.ohrpharmaceutical.com/product-portfolio/squalamine. Accessed December 21 2016.
Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta) Shows No Benefit Over Aflibercept Alone in Neovascular Age-Related Macular Degeneration. PR Newswire website. http://www.prnewswire.com/news-releases/regeneron-announces-phase-2-study-of-aflibercept-co-formulated-with-rinucumab-anti-pdgfr-beta-shows-no-benefit-over-aflibercept-alone-in-neovascular-age-related-macular-degeneration-300337055.html. Published September 30 2016. Accessed December 22 2016.
Jaffe GF, Ciulla TA, Ciardella AP, et al. Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration. Ophthalmology. 2016 Oct 28. pii: S0161–6420(16)31636-0. [Epub ahead of print]
Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista in Wet Age-Related Macular Degeneration. Ophthotech website. http://investors.ophthotech.com/releasedetail.cfm?ReleaseID=1003651. Published December 12 2016. Accessed December 22 2016.
Phase 2A Open Label Safety Study of Fovista (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/NCT02214628. Published August 5 2014. Updated December 19 2016. Accessed December 22 2016.
An 18 Month Phase 2a Open Label Randomized Study of Avastin Lucentis or Eylea (Anti-VEGF Therapy) Administered in Combination With Fovista (Anti-PDGF BB Pegylated Aptamer). ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/NCT02387957. Published March 9 2015. Updated December 19 2016. Accessed December 22 2016.